Encouragingly, a prenylflavonoid derivative, Icaritin, previously identified as a PD-L1 regulator, has been demonstrated to be an IKKα inhibitor; it is currently being investigated in phase III trials as a single agent in China (NCT03236636 and NCT03236649) for the treatment of advanced HCC [41]. Here, CD274 is linked to hepatocellular carcinoma.